Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 12:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 3,338 matching trials from the live ClinicalTrials.gov search.
Conditions
Head and Neck Cancers
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Squamous Cell Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Laryngeal Squamous Cell Carcinoma, Stage IV Laryngeal Verrucous Carcinoma, Stage IV Lip and Oral Cavity Squamous Cell Carcinoma, Stage IV Major Salivary Gland Carcinoma, Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IV Oral Cavity Verrucous Carcinoma, Stage IV Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma, Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary
Interventions
Cediranib Maleate, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Brain Cancer, Thyroid Cancer, Circulatory Disease, Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Head and Neck Cancer
Interventions
Tadalafil, Placebo
Drug · Other
Lead sponsor
Donald T. Weed
Other
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Miami, Florida
Conditions
Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma
Interventions
silicon phthalocyanine 4
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Head and Neck Cancer
Interventions
Oxaliplatin, Radiation
Drug · Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Orange, California
Conditions
Esophageal Cancer
Interventions
wireless pulse oximeter (Wipox)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
Interventions
Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease
Interventions
radiation therapy, surgery, mFOLFIRINOX, FOLFOX
Radiation · Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
154
States / cities
Mobile, Alabama • Antioch, California • Berkeley, California + 122 more
Conditions
Malignant Neoplasm of Skin Head and Neck
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Solid Tumor
Interventions
Rilvegostomig, Volrustomig, Sabestomig, Pembrolizumab, AZD9592, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
9
States / cities
Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more
Conditions
Head and Neck Cancer, Squamous Cell Cancer
Interventions
Afatinib, Ribavirin, and weekly carboplatin/paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Basking Ridge, New Jersey • New York, New York
Conditions
Head and Neck Cancer
Interventions
Couple-Based CBT Intervention
Behavioral
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Evanston, Illinois
Conditions
Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 2 Interventional Results available

Bupropion in Helping Adults Stop Smoking

NCT00534001
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
bupropion hydrochloride, placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Esophageal Cancer
Interventions
liposomal paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
New York, New York
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Interventions
Not listed
Lead sponsor
Adela, Inc
Industry
Eligibility
40 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
17
States / cities
Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Gefitinib, methotrexate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Palm Springs, California + 23 more
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

NCT04106492
Conditions
Cancer
Interventions
SQ3370
Drug
Lead sponsor
Shasqi, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Duarte, California • Palo Alto, California • Santa Monica, California + 4 more
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab, Cetuximab, Methotrexate, Docetaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
15
States / cities
Stanford, California • Tampa, Florida • Atlanta, Georgia + 11 more
Conditions
Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma, Neuroendocrine Tumors, GIST, Malignant
Interventions
Serious Illness Conversation Guide (SICG), Quality of Life (QOL) survey
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Conditions
Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Head and Neck Cancers
Interventions
da Vinci Surgical Robot Platform, Transoral Robotic Surgery
Device · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Conditions
Head and Neck Cancer
Interventions
Cetuximab, Cisplatin, Nab-Paclitaxel, intensity-modulated radiation therapy
Biological · Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Dallas, Texas